SLC22A12 and hyperuricemia: Recently, novel urate transporter 1 (URAT1) inhibitors with higher selectivity, including SHR4640 (Lin et al., 2021), verinurad (Tan et al., 2017), dotinurad (Taniguchi et al., 2019), which have garnered significant attention in the development of anti- hyperuricemia therapy.